Eczema Trial, Recruiting (NCT07645820)

Eczema Trial, Recruiting NCT07645820 Sponsor: Castle Biosciences Incorporated Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07645820 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 12 to 89 years old.
People who have been diagnosed with atopic dermatitis (eczema).
People who have had at least one eczema flare-up in the past 2 months.
People who are willing and able to use a home monitoring device called Nevisense Go, fill in a daily symptom diary on an electronic device, and attend study appointments.
People who are currently on a systemic (whole-body) treatment for eczema, provided that treatment has stayed the same for at least 3 months and there are no plans to change it during the study.

Who may not be able to join:

People who are unwilling or unable to avoid applying creams, lotions, ointments, or soap to the skin areas being measured for 6 hours before each measurement.
People who do not have suitable skin areas available for the study's measurements (confirm with trial site).
People who have another skin condition that could affect how the study assessments are interpreted.
People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 602-499-0301

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07645820

Sponsor: Castle Biosciences Incorporated

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 602-499-0301

More information: https://clinicaltrials.gov/study/NCT07645820

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 12 to 89 years old.
People who have been diagnosed with atopic dermatitis (eczema).
People who have had at least one eczema flare-up in the past 2 months.
People who are willing and able to use a home monitoring device called Nevisense Go, fill in a daily symptom diary on an electronic device, and attend study appointments.
People who are currently on a systemic (whole-body) treatment for eczema, provided that treatment has stayed the same for at least 3 months and there are no plans to change it during the study.

Who may not be able to join:

People who are unwilling or unable to avoid applying creams, lotions, ointments, or soap to the skin areas being measured for 6 hours before each measurement.
People who do not have suitable skin areas available for the study's measurements (confirm with trial site).
People who have another skin condition that could affect how the study assessments are interpreted.
People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Castle Biosciences Incorporated

Registry

ClinicalTrials.gov

Start date

29 May 2026

Est. completion

1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Relationship between skin measurements and subsequent atopic dermatitis flares; Develop and validate an algorithm using Nevisense Go EIS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov